全文获取类型
收费全文 | 2528篇 |
免费 | 125篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 95篇 |
妇产科学 | 20篇 |
基础医学 | 466篇 |
口腔科学 | 83篇 |
临床医学 | 296篇 |
内科学 | 564篇 |
皮肤病学 | 113篇 |
神经病学 | 90篇 |
特种医学 | 281篇 |
外科学 | 199篇 |
综合类 | 53篇 |
预防医学 | 93篇 |
眼科学 | 27篇 |
药学 | 156篇 |
中国医学 | 2篇 |
肿瘤学 | 139篇 |
出版年
2018年 | 26篇 |
2015年 | 32篇 |
2014年 | 28篇 |
2013年 | 88篇 |
2012年 | 44篇 |
2011年 | 33篇 |
2010年 | 55篇 |
2009年 | 36篇 |
2008年 | 34篇 |
2007年 | 65篇 |
2006年 | 62篇 |
2005年 | 49篇 |
2004年 | 33篇 |
2003年 | 40篇 |
2002年 | 35篇 |
2001年 | 39篇 |
2000年 | 29篇 |
1999年 | 50篇 |
1998年 | 87篇 |
1997年 | 97篇 |
1996年 | 107篇 |
1995年 | 73篇 |
1994年 | 75篇 |
1993年 | 77篇 |
1992年 | 54篇 |
1991年 | 48篇 |
1990年 | 52篇 |
1989年 | 73篇 |
1988年 | 67篇 |
1987年 | 57篇 |
1986年 | 58篇 |
1985年 | 43篇 |
1984年 | 60篇 |
1983年 | 33篇 |
1982年 | 33篇 |
1981年 | 40篇 |
1980年 | 49篇 |
1979年 | 26篇 |
1978年 | 29篇 |
1977年 | 37篇 |
1976年 | 41篇 |
1975年 | 37篇 |
1972年 | 25篇 |
1970年 | 23篇 |
1965年 | 50篇 |
1964年 | 50篇 |
1963年 | 47篇 |
1962年 | 41篇 |
1961年 | 40篇 |
1960年 | 65篇 |
排序方式: 共有2685条查询结果,搜索用时 31 毫秒
81.
Epilepsy surgery has emerged as an important option in the treatment of children with epilepsy that is refractory to antiepileptic drug management. The cornerstone of successful surgery is accurate localization of the brain region of seizure onset. Traditional techniques of seizure onset localization, e.g. surface electroencephalography (EEG) recording and magnetic resonance imaging (MRI), allow accurate localization in a significant number of patients. When the focus of seizure onset is not apparent from these non-invasive techniques, other methods of localization, e.g. intracranial EEG recording, may be needed before resection of the focus. Single-photon emission computed tomography (SPECT) is a nuclear medicine blood-flow technique that has been used to identify a region of epileptogenic brain associated with low blood flow in the resting state (interictal SPECT) or increased blood flow at the time of seizure activity (ictal SPECT). This report describes the validation and utility of a computer-assisted method of subtracting the interictal from the ictal SPECT scans and co-registering the difference image on the MRI. This method, called subtraction ictal SPECT co-registered on MRI (SISCOM), is used in guiding the location and the extent of intracranial electrode implantation, or in obviating the need for the implantation in some cases. 相似文献
82.
Louise Burke Douglas B Flieder Donald G Guinee Elizabeth Brambilla Andrew N Freedman William P Bennett Raymond T Jones Andrew Borkowski Neil A Caporaso Marian Fleming Victor Trastek Peter Pairolero Henry Tazelaar David Midthun James R Jett Lance A Liotta William D Travis Curtis C Harris 《Clinical cancer research》2005,11(1):232-241
PURPOSE: Many studies have highlighted the aberrant expression and prognostic significance of individual proteins in either the Rb (particularly cyclin D1, p16INK4A, and pRb) or the p53 (p53 and p21Waf1) pathways in non-small cell lung cancer. We hypothesize that cumulative abnormalities within each and between these pathways would have significant prognostic potential regarding survival. EXPERIMENTAL DESIGN: Our study population consisted of 106 consecutive surgically resected cases of predominantly early-stage non-small cell lung cancer from the National Cancer Institute-Mayo Clinic series, and assessment of proteins involved both immunohistochemical (cyclin D1, p21Waf1, pRb, p16INK4A, and p53) and mutational analysis (p53) in relationship to staging and survival. RESULTS: Cyclin D1 overexpression was noted in 48% of the tumors, p16INK4A negative in 53%, pRb negative in 17%, p53 immunopositive in 50%, p53 mutation frequency in 48%, and p21(Waf1) overexpression in 47%, none with prognostic significance. Cyclin D1 overexpression in pRb-negative tumors revealed a significantly worse prognosis with a mean survival of 2.3 years (P = 0.004). A simultaneous p53 mutation dramatically reduced the mean survival time to 0.9 years (P = 0.007). Cyclin D1 overexpression with either a p53 mutation or a p53 overexpression was also associated with a significantly poorer prognosis (P = 0.0033 and 0.0063, respectively). CONCLUSIONS: Some cumulative abnormalities in the Rb and p53 pathways (e.g., cyclin D1 overexpression and p53 mutations) significantly cooperate to predict a poor prognosis; however, the complexity of the cell cycle protein interaction in any given tumor warrants caution in interpreting survival results when specific protein abnormalities are taken in isolation. 相似文献
83.
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. 总被引:1,自引:0,他引:1
Cynthia X Ma Suresh Nair Sachdev Thomas Sumithra J Mandrekar Daniel A Nikcevich Kendrith M Rowland Tom R Fitch Harold E Windschitl Shauna L Hillman Steven E Schild James R Jett Coleman Obasaju Alex A Adjei 《Journal of clinical oncology》2005,23(25):5929-5937
PURPOSE: A randomized three-arm phase II study was undertaken to evaluate the optimum administration schedule of pemetrexed and gemcitabine in chemotherapy-na?ve patients with non-small-cell lung cancer. PATIENTS AND METHODS: Patients were randomly assigned to three schedules of pemetrexed 500 mg/m2 plus gemcitabine 1,250 mg/m2, separated by a 90-minute interval, on a 21-day cycle as follows: schedule A, pemetrexed followed by gemcitabine on day 1 and gemcitabine on day 8; schedule B, gemcitabine followed by pemetrexed on day 1 and gemcitabine on day 8; and schedule C, gemcitabine on day 1 and pemetrexed followed by gemcitabine on day 8. RESULTS: One hundred fifty-two eligible patients (schedule A, n = 59; schedule B, n = 31, and schedule C, n = 62) received a median of five (schedule A), two (schedule B), and four (schedule C) treatment cycles. Overall, 66% of patients experienced grade 3 or 4 neutropenia. Common grade 3 and 4 nonhematologic toxicities were dyspnea (11%), fatigue (16%), and transaminase elevation (9%). Schedule A seemed less toxic compared with schedule C (grade 3 or 4 events: 86% v 94%, respectively; P = .19; grade 4 events: 39% v 48%, respectively; P = .30). Schedule B was closed at interim analysis for inferior efficacy. Schedule A, with a confirmed response rate of 31% (95% CI, 20% to 45%), met the protocol-defined efficacy criteria, whereas schedule C, with a confirmed response rate of 16.1% (95% CI, 11% to 34%), did not. Median survival time and time to progression were 11.4 and 4.4 months, respectively, with no observable difference between the arms. CONCLUSION: Pemetrexed and gemcitabine administered as outlined for schedule A met the protocol-defined efficacy criteria, was less toxic compared with the other treatment schedules, and should be further evaluated. 相似文献
84.
E García‐Molina J Lacunza F Ruiz‐Espejo M Sabater A García‐Alberola JR Gimeno F Caizares A García P Martínez M Valds I Tovar 《Clinical genetics》2013,83(6):530-538
We aim to study the SCN5A gene in a cohort of Brugada syndrome (BS) patients and evaluate the genotype–phenotype correlation. BS is caused by mutations in up to 10 different genes, SCN5A being the most frequently involved. Large genomic rearrangements in SCN5A have been associated with conduction disease, but its prevalence in BS is unknown. Seventy‐six non‐related patients with BS were studied. Clinical characteristics and family risk profile were recorded. Direct sequencing and multiplex ligation‐dependent probe amplification (MLPA) of the SCN5A gene for identification of mutations and larger rearrangements were performed, respectively. Eight patients (10.5%) had point mutations (R27H, E901K, G1743R (detected in three families), V728I, N1443S and E1152X). Patients with mutations had a trend toward a higher proportion of spontaneous type I Brugada electrocardiogram (ECG) (87.5% vs 52.9%, p = 0.06) and had evidence of familial disease (62.5%, vs 23.5%, p = 0.03). The symptoms and risk profile of the carriers were not different from wild‐type probands. There were non‐significant differences in the prevalence of type I ECG, syncope and history of arrhythmia in carriers of selected polymorphisms. None of the patients had any deletion/duplication in the SCN5A gene. In conclusion, 10.5% of our patients had mutations in the SCN5A gene. Patients with mutations seemed to have more spontaneous type I ECG, but no differences in syncope or arrhythmic events compared with patients without mutations. Larger studies are needed to evaluate the role of polymorphisms in the SCN5A in the expression of the phenotype and prognosis. Large rearrangements were not identified in the SCN5A gene using the MLPA technique. 相似文献
85.
86.
87.
88.
89.
90.